MYL5 and breast cancer: The results showed that in Kaplan–Meier plotter and PrognoScan databases, the overall survival (OS), distant metastases-free survival (DMFS), relapse-free survival (RFS), and postprogression survival (PPS) of breast cancer patients in the MYL5 high-expression group were all significantly longer than the MYL5 low-expression group (Figures 3(a)–3(d)).